Hypertrophic Cardiomyopathy (HCM)

Prevalence of HCM

HCM is inherited as an autosomal dominant disease in both humans (Liu et al., 1993; Maron et al., 2003) and cats (Meurs et al., 2007; Meurs et al., 2005). It is the most prevalent cardiomyopathy disease in both species; however, several factors preclude accurate determination of the disease frequency. It has been estimated to affect 0.1 - 0.2% of the human population and is the leading cause of sudden cardiac death in adolescents (including competitive athletes) (Maron et al., 1995). In cats the prevalence is high and it is estimated close to 16% of the overtly healthy cat population are affected (Cote et al., 2004; Paige et al., 2009; Riesen et al., 2007a). A retrospective echocardiographic study reported that 57.5% of cats initially diagnosed as idiopathic cardiomyopathy (n = 106) were found to have HCM (Ferasin et al., 2003).

HCM is a disease of young-to-middle age cats between 8 months to 16 year (mean of onset around 6.5 year) (Kraus et al., 1999; Nakagawa et al., 2002). The youngest documented was 2 months old (Fujii et al., 2001) and was commonly observed in males (Fujii et al., 2001; Granstrom et al., 2011; Liu et al., 1981; Riesen et al., 2007a; Tilley et al., 1977), a pattern which is not seen in humans. Male cats were also observed predisposed to HCM earlier in life and with a more aggressive development of the disease (Atkins et al., 1992; Rush et al., 2002), compared to female cats.

Generally, cats are a sedentary animal by nature but stressful situations (e.g. cat fights or chased by dog – increased sympathetic activity of the heart), may induce sudden death in cats with asymptomatic HCM (Kittleson and Kienle, 1998). A cross-sectional echocardiographic study identified a high frequency of 8 - 10% HCM amongst overtly healthy cats (Riesen et al., 2007a), which suggested that substantial changes to the heart were apparent well before any clinical signs were observed. This asymptomatic incidence of HCM partially explains episodes of sudden death or aortic thromboembolism that occurs in apparently young healthy cats without any obvious clinical signs (Baty et al., 2001; Cote et al., 2004; Liu and Tilley, 1980; Riesen et al., 2007b). Two large retrospective studies reported that the median survival time for cats presented with aortic thromboembolism, congestive heart failure and asymptomatic cats were between 2 to 6 months, 6 to 18 months and 3 to 5 years, respectively (Atkins et al., 1992; Rush et al., 2002).

Genetic factors of HCM

Abnormalities in the encoding sarcomeric proteins identified in HCM patients have led to a theory that it is a disease of contractile sarcomeric proteins (Marian and Roberts, 2001). HCM in humans is caused by a genetic mutation in one of the genes that encode for the sarcomeric proteins including β-myosin heavy chain (MyHC), cardiac troponin T and myosin binding protein C gene (MyBP-C) (Marian and Roberts, 2001; Maron, 2002). Other genes that accounted for a minority of human HCM cases were cardiac troponin I, regulatory and essential myosin light chain, titin, α-tropomyosin, α-actin and α-myosin heavy chain (Ommen and Nishimura, 2004). In human, HCM is inherited, usually as a heterogeneous autosomal dominant trait, in at least 2/3 of all HCM cases (Marian and Roberts, 2001; Solomon et al., 1990). To date, more than 1000 different mutations have been identified within 13 myofilament-related genes in human (Alcalai et al., 2008; Davies and Krikler, 1994; Solomon et al., 1990).

In cats, recent studies in Maine Coon and Ragdoll breeds have identified defects in the same sarcomeric protein genes, MyBP-C, but in different locations (Kittleson et al., 1998; Meurs et al., 2008; Meurs et al., 2007; Meurs et al., 2005), heritable in an autosomal dominant pattern (Baty and Walkins, 1998; Fananapazir and Epstein, 1994; Kittleson et al., 1999; Meurs et al., 2005). In addition to these breeds, there is anecdotal evidence of the familial heritability of HCM in other breeds, including Persian, British Shorthair, Norwegian Forest Cat, Turkish Van, Scottish Fold, Siberian, Sphynx and others (Granstrom et al., 2011; Meurs et al., 2009; Tilley et al., 2008), although the exact genetic cause in these breeds have not been well studied. The familial nature of HCM has also been reported in domestic (mixed-breed) cats (Kraus et al., 1999; Nakagawa et al., 2002). A long term observation on the progression of HCM in a family of domestic shorthair cat has been documented (Baty et al., 2001).

HCM in Maine Coon cats closely resembles human familial HCM in terms of mode of inheritance, phenotypic expression and disease course (Fananapazir and Epstein, 1994; Kittleson et al., 1999; Meurs et al., 2005). Recent study have found that the MyBP-C gene mutation in Maine Coon cats is breed specific and may not appears to be

*Corresponding author: Dr Khor Kuan Hua (K.H. Khor); Phone:+603 8609 3926; Email:khkhor@upm.edu.my.
associated with the familial HCM in other breed of cats. The mutation is inherited with incomplete penetrance (heterozygous) with variable expressivity where not all cats with the mutation will show the disease or the severity of the disease may varies among cats (Figure 1) (Carlos Sampedrano et al., 2009; Lyons, 2010; Meurs et al., 2005). Carlos Sampedrano et al. (2009) identified 18% of Maine Coon cats (n = 8/44) with MyBP-C has HCM, hence not all cats with the identified gene developed HCM. The actual prevalence may have been underestimated and probably a long-term follow-up would accurately establish the onset of disease and its effects on all ages of cats. It was also suggested that there are likely more than one mutation responsible for HCM in this breed (Carlos Sampedrano et al., 2009). In Ragdoll cats, the substitution mutation identified in the MyBP-C, differs from the Maine Coon cats because the mutation is located in a different region. Therefore, Maine Coon and Ragdoll cats’ mutations were unlikely inherited from a common ancestor. The mode of inheritance in Ragdoll cats is yet to be identified and this breed-specific mutation has not been identified in other breeds of cats. In Ragdoll cats, it was shown that the homozygous cats appeared to be very severely affected, often before 2 years of age and the heterozygous cats appeared to have a milder form of the disease (Meurs et al., 2007).

In summary, the identification of the first sarcomeric gene mutation, MyBP-C in Maine Coon cats is highly significant and supports a role for cats as an alternative to transgenic mice as a animal model of human familial HCM (Figure 1) (Baty, 2004; Baty and Walkins, 1998; Hasenfuss, 1998).

Pathogenesis and progression of HCM

It is a primary disorder of the myocardium characterised by concentric left ventricular hypertrophy, can be further described as mild-to-severe (thicken wall of a normal-to-small chamber size) (Kittleson and Kienle, 1998). To distinguish either: mild hypertrophy from normal, mild-to-moderate hypertrophy, severe hypertrophy or secondary due to other abnormalities are often not easy (Boon, 1998; Fox et al., 1999; Moise et al., 1986). HCM is phenotypically heterogeneous and no single distribution of left ventricular hypertrophy is typical of the disease (Kittleson and Kienle, 1998). Many have compared and correlated echocardiography findings with other diagnostic methods such as electrocardiography, necropsy, histopathology and computed magnetic resonant imaging to correlated the site or severity of hypertrophy and clinical findings (Fox, 2003; Sato et al., 1998).

HCM consist of two forms; obstructive and non-obstructive. Hypertrophy obstructive cardiomyopathy (HOCM) occurs when the hypertrophied basilar interventricular septum impinges and results in narrowing of the left ventricular outflow tract. The mitral valve is pushed into the outflow tract causing systolic anterior motion (SAM) of the mitral valve causing further obstruction of the outflow tract. At the onset of SAM of the mitral valve in HCM patients, the pushing force of flow is caused by the dominant hydrodynamic force (Sherrid et al., 2000), although the Venturi force are present in the outflow tract but does not contribute to the mechanism of SAM. Hence, the obstruction may be either dynamic, fixed or both (Boon, 1998; French, 2008; Takemura et al., 2003). SAM of the mitral valve is infrequently reported in cats with HCM but one isolated report by Fox et al. (1995) found that SAM was a common abnormality identified in 67% of the HCM cats (n=46). However, this condition may not present in all HCM cats and some cats may develop this condition before any evidence of wall thickening or some cats may have SAM of the mitral valve as a primary disease (Fox et al., 1995; Kittleson and Kienle, 1998; Klues et al., 1993) and similar has been widely studied and reported in HCM patients (Klues et al., 1993; Spirito and Maron, 1984).
Therefore, it is important to distinguish between obstructive and non-obstructive forms of HCM, as clinical decisions depend on the presence or absence of outflow obstruction (Kittleson and Kienle, 1998). SAM of the mitral valve produce two abnormalities where: (i) it obstructs blood flows out of the left ventricle in systole (dynamic sub-aortic stenosis) causing an increase blood flow velocity through the sub-aortic region producing a turbulence and; (ii) the septal leaflet drawn out from its normal position creates a mitral regurgitation due to SAM (Kittleson and Kienle, 1998). Dynamic outflow tract obstruction if severe will be a stimulus for concentric hypertrophy and potentially worsen left ventricular diastolic dysfunction. Hence, coupled with other structural pathological change (i.e. myocardial fibre disarray, myocardial fibrosis), it may exacerbate or potentially accelerate progression to heart failure.

**Gross pathology**

Cats with severe HCM have severe thickening of the left ventricular myocardium [the interventricular septum (IVS) and left ventricular free wall (LVFW)], papillary muscle hypertrophy and left atrium enlargement with possible thrombus present. The left ventricular chamber is smaller than normal due to the inwards myocardial thickening into the left ventricular cavity (Cesta et al., 2005; Fox, 2003; Liu et al., 1981; Liu et al., 1993; Tilley et al., 1977). The distributions of the myocardium thickness in most cases may not be the same. The IVS and the LVFW are equally thickened (symmetric hypertrophy) in most cats with severe HCM. Other cats may have significantly thicker IVS compared to the LVFW or vice versa. Cats with mild-to-moderate HCM have lesser myocardial wall thickness, hypertrophy papillary muscle and probably a normal size of left ventricular and atrium chamber (Fox et al., 1999; Kittleson and Kienle, 1998; Tilley et al., 2008). Heart weight was reported to be a useful indicator for disease severity or to identify hearts with hypertrophy grossly. The heart weight in relation to the body weight has been reported to be 4.8 ± 1.8 g/kg in healthy cats versus 6.0 ± 1.4g/kg in cats with HCM (Fox et al., 1995).

**Histopathology**

HCM has a wide range of histopathological abnormalities but myocardial fibre disarray is a distinctive hallmark of HCM. The myocytes are arranged in chaotic, disorganised patterns at oblique and/or perpendicular angle which appeared in a bizarre disorganised cellular architecture (Baty et al., 2001; Fox, 2003; Kittleson and Kienle, 1998; Liu et al., 1993; Nakagawa et al., 2002; Tilley et al., 1977). Other histopathological findings are hypertrophied myocytes, increased collagen deposition resulting interstitial fibrosis and abnormalities of the intramyocardial small vessels (Cesta et al., 2005; Fox, 2003; Liu et al., 1993; Nakagawa et al., 2002; Varnava et al., 2000). It is likely that these abnormal structural changes disrupt the transmission of electrophysiology impulses predisposing the diseased heart to diastolic dysfunction and ventricular tachyarrhythmia (Fox, 2003; Kittleson and Kienle, 1998; Liu et al., 1981; Liu et al., 1993; Tilley et al., 1977). The frequency of each abnormality observed varied between HCM cats (Liu et al., 1993). Liu et al. (1981) found 25% of the HCM cats (n=51) observed with asymmetric left ventricular hypertrophy had myocardial fibre disarray in the IVS. In other HCM hearts, only myocyte hypertrophy was evident or some had moderate-to-severe interstitial. Replacement fibrosis was present in about 20 - 40% of HCM cases (Liu et al., 1993). The histopathological findings differ between HCM hearts probably due to cardiac remodelling which occurs at different stages of the disease, maybe depending on the extent of the damage. Hence, whether the asymptomatic cats with HCM have similar histopathological findings at the early stage despite detectable functional changes is unknown and warrant investigation.

**Pathophysiology**

The pathogenesis of HCM in both humans and cats, to our knowledge is still not fully understood. It is a known genetic cardiovascular disease due to the mutations in genes encoding proteins of the cardiac sarcomere, but the molecular pathogenesis that leads to the development of hypertrophy and the variability in the common pathological phenotypes expression still remain unknown (Abbott, 2010; Braundwald et al., 2012; Lind et al., 2006; Marian, 2000; Maron et al., 2009). A mouse model has recently been used to gain greater understanding of this complex genetic disorder (Berul et al., 2001; Geisterfer-Lowrance et al., 1996; James et al., 1998; Prabhakar et al., 2003; Shephard and Semsarian, 2009; Welikson et al., 1999) as studies of molecular and pathophysiological mechanisms in cats or human HCM patients is difficult, particularly since the disease is often well established before diagnosis, especially
in cats. Pathophysiological changes and/or dysfunction presence at the early stage of HCM in cats well before the clinical sign was observed but actual mechanism is still widely debated. The genetic mutation or the pathophysiological mechanism is a trigger of the HCM is still unknown, to our knowledge.

What is understood now are that in any particular HCM cat, one or more of the pathophysiological changes and dysfunctions may occur including: (i) left ventricular diastolic dysfunction; (ii) ventricular and supraventricular tachyarrhythmias; and (iii) myocardial ischemia and fibrosis (Kittleson and Kienle, 1998; Maron et al., 2009; Tilley et al., 2008). Coupled with those important derangements, there are other under-recognised emerging pathophysiological concerns such as the possible presences of myocarditis (Bayes-Genis, 2007) and autonomic nervous dysfunction (Morner et al., 2005) to our knowledge has not been given emphasis in cats with HCM.

**Left ventricular diastolic dysfunction**

The main functional implication in cats with HCM is diastolic dysfunction (Fox et al., 1999; Kittleson and Kienle, 1998; Tilley et al., 2008). The pathological changes of the concentric left ventricular hypertrophy from cardiac remodelling increased myocardial stiffness, increased end diastolic filling pressure and impaired early diastolic relaxation (Abbott, 2000; Fox, 2007; Liu et al., 1993).

In HCM, diastolic function is compromised by several mechanisms. Ventricle compliance is reduced as a result of left ventricular hypertrophy and small arterial changes that impair left ventricular perfusion, causing myocardial ischemia, necrosis and replacement fibrosis (Kitamura et al., 2001; Kittleson and Kienle, 1998). Compliance is further compromised by myocardial fibre disarray which has been shown as the most important factor related to diastolic dysfunction in humans HCM (Osato et al., 1989) but assumed to contribute similar consequences in cats with HCM (Kittleson et al., 1999). Besides that, impaired sarcoplasmic calcium channel regulation and impaired calcium uptake by the sarcoplasmic reticum leads to increased intracellular calcium concentration and impaired active relaxation (Gwathmey et al., 1991; Opie, 2004).

**Ventricular and supraventricular tachyarrhythmias**

Correlation between left ventricular hypertrophy and arrhythmogenic sudden death is well established not only in HCM, but in other conditions that contribute to left ventricular hypertrophy (i.e. hypertensive and aortic stenosis) (Douglas and Tallant, 1991; Piorecka-Makula and Werner, 2009; Wolk, 2000). The most consistently observed abnormality that predisposed to arrhythmia is early or delayed afterdepolarisation and triggered activity leading to prolong action potential durations and refractoriness. In addition, non-uniform prolongation of the action potential may lead to increased dispersion of repolarisation or refractoriness and favouring re-entry in the heart (Levick, 2003; Strickland, 1998; Wolk, 2000). In humans with HCM, the disorganised cellular architecture, myocardial fibrosis and scarring due to cardiac remodelling has been suspected as an arrhythmogenic substrate predisposing to the life-threatening electrical instability (Marian and Roberts, 2001; Ommen and Nishimura, 2004; Spirito et al., 1987).

Spirito et al. (1987) documented a strong association of severe-to-moderate left ventricular hypertrophy with significantly increased occurrences of ventricular tachycardia in HCM patients. Cats with a history of episodic collapse or dyspnoea diagnosed with HCM were identified with a high frequency of severe ventricular arrhythmias (i.e. ventricular premature complexes, ventricular bigeminy, ventricular tachycardia, supraventricular tachycardia, supraventricular premature complex) (Bright and Cali, 2000; Ferasin et al., 2003; Goodwin et al., 1992).

**Myocardial ischaemic and fibrosis**

Application of positron emission topography and cardiovascular magnetic resonant has allowed evaluation of active myocardial ischemia as a determinant of progressive heart failure in human HCM patients (Harris et al., 2006; O’Gara et al., 1987; Olivotto et al., 2004). The combination of increased left ventricular wall thickness (increased myocardial oxygen demand) and decreased capillary network (decreased myocardial oxygen supply) will increase heart rate and afterload, while decreased perfusion may predispose to myocardial ischemia (Ommen and Nishimura, 2004).

Presence of myocardial ischemia due to microvascular dysfunction in HCM has been suggested as an important pathophysiological component of the disease progression (Maron et al., 2009). Cats with HCM have coronary remodelling (arteriosclerosis or “small vessel disease”) similar to that described in humans with HCM (Baty et al., 2001; Nakagawa et al., 2002; Takekura et al. 2003). Liu et al. (1993) identified intramural coronary arteriosclerosis in 75% (38/51) of cats diagnosed with HCM. Both, Varnava et al. (2002) and Liu et al. (1993) described a common finding and relate that the intramural coronary arteriosclerosis are particularly prominent in tissue sections with moderate-to-severe fibrosis. There may therefore be a relationship between arteriosclerosis and myocardial fibrosis. With compromised blood flow in small vessels triggering myocardial ischemia, with subsequent cell death (necrosis) and scarring (fibrosis) affecting the clinical course of the disease.

Varnava et al. (2000) proposed that myocardial fibre disarray was a direct response to the functional and structural abnormalities of the mutated sarcomeric protein, although the authors also considered that fibrosis and small vessel disease were secondary response unrelated to disarray. Myocardial ischemia has been linked to
ventricular tachycardia and sudden death (Wolk, 2000) and its presence in the early stages of HCM may actually be a pathogenic factor.

REFERENCES


